Display options
Cite
Abdullah I, Alhendi G, Alhadab A, et al. Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease. Front Med (Lausanne). 2021;8:725512doi: 10.3389/fmed.2021.725512.
Abdullah, I., Alhendi, G., Alhadab, A., Alasfour, H., & Shehab, M. (2021). Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease. Frontiers in medicine, 8725512. https://doi.org/10.3389/fmed.2021.725512
Abdullah, Israa, et al. "Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease." Frontiers in medicine vol. 8 (2021): 725512. doi: https://doi.org/10.3389/fmed.2021.725512
Abdullah I, Alhendi G, Alhadab A, Alasfour H, Shehab M. Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease. Front Med (Lausanne). 2021 Sep 29;8:725512. doi: 10.3389/fmed.2021.725512. eCollection 2021. PMID: 34660635; PMCID: PMC8511459.
Copy Download .nbib Format: NLM
Share it on

Front Med (Lausanne). 2021 Sep 29;8:725512. doi: 10.3389/fmed.2021.725512. eCollection 2021.

Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease.

Frontiers in medicine

Israa Abdullah, Ghadeer Alhendi, Anwar Alhadab, Hajer Alasfour, Mohammad Shehab

Affiliations

  1. Department of Pharmacy Practice, Faculty of Pharmacy, Kuwait University, Kuwait City, Kuwait.
  2. Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Kuwait City, Kuwait.

PMID: 34660635 PMCID: PMC8511459 DOI: 10.3389/fmed.2021.725512

[No abstract available.]

Copyright © 2021 Abdullah, Alhendi, Alhadab, Alasfour and Shehab.

Keywords: IBD; age; anti-TNF; combination; gastroenterologist; interest

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Gastroenterology. 2014 Feb;146(2):392-400.e3 - PubMed
  2. Inflamm Bowel Dis. 2016 Aug;22(8):1999-2015 - PubMed
  3. J Crohns Colitis. 2016 Nov;10(11):1259-1266 - PubMed
  4. Dig Liver Dis. 2019 Mar;51(3):346-351 - PubMed
  5. J Crohns Colitis. 2017 Jul 1;11(7):769-784 - PubMed
  6. Gut. 2020 Jul;69(7):1206-1212 - PubMed
  7. Gastroenterology. 2017 Sep;153(3):827-834 - PubMed
  8. J Crohns Colitis. 2020 Jan 1;14(1):4-22 - PubMed
  9. Inflamm Bowel Dis. 2017 Dec 19;24(1):191-197 - PubMed
  10. J Crohns Colitis. 2014 Dec;8(12):1632-41 - PubMed
  11. Inflamm Bowel Dis. 2017 Aug;23(8):1316-1327 - PubMed
  12. Epidemiology. 2007 Nov;18(6):800-4 - PubMed
  13. BioDrugs. 2017 Aug;31(4):299-316 - PubMed
  14. Gastroenterology. 2018 Apr;154(5):1343-1351.e1 - PubMed
  15. Gastroenterology. 2020 Apr;158(5):1450-1461 - PubMed
  16. N Engl J Med. 2010 Apr 15;362(15):1383-95 - PubMed
  17. Gastroenterology. 2015 Jun;148(7):1320-9.e3 - PubMed
  18. Inflamm Bowel Dis. 2017 Sep;23(9):1510-1515 - PubMed
  19. Therap Adv Gastroenterol. 2018 Jan 21;11:1756283X17750355 - PubMed
  20. Gastroenterology. 2021 Jun;160(7):2496-2508 - PubMed
  21. J Crohns Colitis. 2018 Jun 28;12(7):804-810 - PubMed

Publication Types